Carillon Tower Remains Optimistic in Seagen (SGEN) Despite its Poor Performance

Carillon Tower Advisers, an investment management firm, published its fourth quarter 2020 “Carillon Eagle Mid Cap Growth Fund” investor letter – a copy of which can be downloaded here. In the letter, the fund talked about their best and worst securities, together with their outlook for this year from an investment perspective. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

Carillon Tower Advisers, in their Q4 2020 investor letter, mentioned Seagen Inc. (NASDAQ: SGEN) and emphasized their views on the company. Seagen Inc. is a Bothell, Washington-based biotechnology company that currently has a $25.4 billion market capitalization. Since the beginning of the year, SGEN delivered a -19.96% return, while its 12-month gains are still up by 32.93%. As of March 24, 2021, the stock closed at $140.19 per share.

Here is what Carillon Tower Advisers has to say about Seagen Inc. in their Q4 2020 investor letter:

“Seagen is a biotechnology company engaged in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The stock slumped a bit in the quarter after the firm announced it was lowering guidance for its drug Adcetris, which is an antibody medication used to treat lymphoma. We remain optimistic on the stock, primarily due to the company’s appealing pipeline of new products as well as the continued growth of Padcev (for metastatic urothelial cancer) and Tucatinib (for breast cancer).”


Our calculations show that Seagen Inc. (NASDAQ: SGEN) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Seagen Inc. was in 95 hedge fund portfolios, compared to 80 funds in the third quarter. SGEN delivered a -26.68% return in the past 3 months.